Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SLOUGH, U.K., Aug. 30, 2005 (PRIMEZONE) -- Xenova Group plc ("Xenova") (Nasdaq:XNVA)(LSE:XEN) is pleased to announce that the scheme of arrangement and the reduction of capital comprised within the...
-
SLOUGH, U.K., Aug. 8, 2005 (PRIMEZONE) -- Xenova Group Plc ("Xenova") (Nasdaq:XNVA) (LSE:XEN) is pleased to announce that, at a Court Meeting and an Extraordinary General Meeting ("EGM") of its...
-
SLOUGH, U.K., June 24, 2005 (PRIMEZONE) -- Xenova Group plc: Summary The Directors of Xenova and the Board of Celtic Pharma announce that they have reached agreement on the terms of a recommended...
-
SLOUGH, U.K., May 23, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the quarter ended 31 March 2005. Year to Date Highlights -- TransMID(TM):...
-
SLOUGH, U.K., April 13, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that it has entered into a licensing agreement for its lead product candidate, TransMID(TM), with...
-
SLOUGH, U.K., March 3, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the year ended 31 December 2004. Announced Today -- TA-NIC preliminary 12...
-
SLOUGH, U.K., March 3, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced preliminary 12 month findings from the second Phase I trial of TA-NIC, the Company's therapeutic...
-
SLOUGH, U.K., Feb. 14, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that, Sosei Co. Ltd. (Sosei) (4565, Tokyo Stock Exchange MOTHERS Index), its licensee for the...
-
SLOUGH, U.K., Jan. 13, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced it has signed an exclusive licensing agreement with Oxxon Therapeutics Ltd (Oxxon) potentially...
-
SLOUGH, U.K., Jan. 10, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that it has entered into a licensing agreement with Cancer Research Technology Limited (CRT) in...